194 related articles for article (PubMed ID: 29463369)
1. Glycyrrhetinic Acid-Modified Norcantharidin Nanoparticles for Active Targeted Therapy of Hepatocellular Carcinoma.
Zhang H; Jiang Y; Ni X; Chen L; Wu M; Liu J; Yang B; Shan X; Yang L; Fan J; Chen Y; Wu J; Fu S
J Biomed Nanotechnol; 2018 Jan; 14(1):114-126. PubMed ID: 29463369
[TBL] [Abstract][Full Text] [Related]
2. Folate receptor-targeted liposomes loaded with a diacid metabolite of norcantharidin enhance antitumor potency for H22 hepatocellular carcinoma both in vitro and in vivo.
Liu MC; Liu L; Wang XR; Shuai WP; Hu Y; Han M; Gao JQ
Int J Nanomedicine; 2016; 11():1395-412. PubMed ID: 27110110
[TBL] [Abstract][Full Text] [Related]
3. Norcantharidin-associated galactosylated chitosan nanoparticles for hepatocyte-targeted delivery.
Wang Q; Zhang L; Hu W; Hu ZH; Bei YY; Xu JY; Wang WJ; Zhang XN; Zhang Q
Nanomedicine; 2010 Apr; 6(2):371-81. PubMed ID: 19699319
[TBL] [Abstract][Full Text] [Related]
4. Intratumoral Administration of Thermosensitive Hydrogel Co-Loaded with Norcantharidin Nanoparticles and Doxorubicin for the Treatment of Hepatocellular Carcinoma.
Gao B; Luo J; Liu Y; Su S; Fu S; Yang X; Li B
Int J Nanomedicine; 2021; 16():4073-4085. PubMed ID: 34163160
[TBL] [Abstract][Full Text] [Related]
5. Development of Glycyrrhetinic Acid and Folate Modified Cantharidin Loaded Solid Lipid Nanoparticles for Targeting Hepatocellular Carcinoma.
Xu Y; Wang M; Ning S; Yang Z; Zhou L; Xia X
Molecules; 2022 Oct; 27(20):. PubMed ID: 36296377
[TBL] [Abstract][Full Text] [Related]
6. N-trimethyl chitosan nanoparticle-encapsulated lactosyl-norcantharidin for liver cancer therapy with high targeting efficacy.
Guan M; Zhou Y; Zhu QL; Liu Y; Bei YY; Zhang XN; Zhang Q
Nanomedicine; 2012 Oct; 8(7):1172-81. PubMed ID: 22321383
[TBL] [Abstract][Full Text] [Related]
7. Treatment for Hepatocellular Carcinoma Is Enhanced When Norcantharidin Is Encapsulated in Exosomes Derived from Bone Marrow Mesenchymal Stem Cells.
Liang L; Zhao L; Wang Y; Wang Y
Mol Pharm; 2021 Mar; 18(3):1003-1013. PubMed ID: 33527831
[TBL] [Abstract][Full Text] [Related]
8. Norcantharidin combined with ABT-737 for hepatocellular carcinoma: Therapeutic effects and molecular mechanisms.
Ren J; Li G; Zhao W; Lin L; Ye T
World J Gastroenterol; 2016 Apr; 22(15):3962-8. PubMed ID: 27099439
[TBL] [Abstract][Full Text] [Related]
9. Hepatocellular carcinoma dually-targeted nanoparticles for reduction triggered intracellular delivery of doxorubicin.
Mezghrani O; Tang Y; Ke X; Chen Y; Hu D; Tu J; Zhao L; Bourkaib N
Int J Pharm; 2015 Jan; 478(2):553-68. PubMed ID: 25455765
[TBL] [Abstract][Full Text] [Related]
10. FAM46C is critical for the anti-proliferation and pro-apoptotic effects of norcantharidin in hepatocellular carcinoma cells.
Zhang QY; Yue XQ; Jiang YP; Han T; Xin HL
Sci Rep; 2017 Mar; 7(1):396. PubMed ID: 28341836
[TBL] [Abstract][Full Text] [Related]
11. Enhanced targeted delivery of adenine to hepatocellular carcinoma using glycyrrhetinic acid-functionalized nanoparticles in vivo and in vitro.
Wu F; Xue H; Li X; Diao W; Jiang B; Wang W; Yu W; Bai J; Wang Y; Lian B; Feng W; Sun T; Qu M; Zhao C; Wang Y; Wu J; Gao Z
Biomed Pharmacother; 2020 Nov; 131():110682. PubMed ID: 32947204
[TBL] [Abstract][Full Text] [Related]
12. Glycyrrhetinic acid-decorated and reduction-sensitive micelles to enhance the bioavailability and anti-hepatocellular carcinoma efficacy of tanshinone IIA.
Chen F; Zhang J; He Y; Fang X; Wang Y; Chen M
Biomater Sci; 2016 Jan; 4(1):167-82. PubMed ID: 26484363
[TBL] [Abstract][Full Text] [Related]
13. Multifunctional self-assembled micelles of galactosamine-hyaluronic acid-vitamin E succinate for targeting delivery of norcantharidin to hepatic carcinoma.
Jiang S; Li M; Hu Y; Zhang Z; Lv H
Carbohydr Polym; 2018 Oct; 197():194-203. PubMed ID: 30007605
[TBL] [Abstract][Full Text] [Related]
14. Doxorubicin-loaded glycyrrhetinic acid modified recombinant human serum albumin nanoparticles for targeting liver tumor chemotherapy.
Qi WW; Yu HY; Guo H; Lou J; Wang ZM; Liu P; Sapin-Minet A; Maincent P; Hong XC; Hu XM; Xiao YL
Mol Pharm; 2015 Mar; 12(3):675-83. PubMed ID: 25584860
[TBL] [Abstract][Full Text] [Related]
15. Effector mechanisms of norcantharidin-induced mitotic arrest and apoptosis in human hepatoma cells.
Chen YN; Chen JC; Yin SC; Wang GS; Tsauer W; Hsu SF; Hsu SL
Int J Cancer; 2002 Jul; 100(2):158-65. PubMed ID: 12115564
[TBL] [Abstract][Full Text] [Related]
16. Hepatocellular Carcinoma Targeting and Pharmacodynamics of Paclitaxel Nanoliposomes Modified by Glycyrrhetinic Acid and Ferric Tetroxide.
Zhao L; Liang L; Guo M; Li M; Yu X; Wang Y; Wang Y
Curr Top Med Chem; 2021 Oct; 21(14):1268-1284. PubMed ID: 34620053
[TBL] [Abstract][Full Text] [Related]
17. A new core-shell-type nanoparticle loaded with paclitaxel/norcantharidin and modified with APRPG enhances anti-tumor effects in hepatocellular carcinoma.
Xie MH; Fu ZL; Hua AL; Zhou JF; Chen Q; Li JB; Yao S; Cai XJ; Ge M; Zhou L; Wu J
Front Oncol; 2022; 12():932156. PubMed ID: 36185205
[TBL] [Abstract][Full Text] [Related]
18. In-vivo anti-tumor activity of a novel poloxamer-based thermosensitive in situ gel for sustained delivery of norcantharidin.
Xie MH; Ge M; Peng JB; Jiang XR; Wang DS; Ji LQ; Ying Y; Wang Z
Pharm Dev Technol; 2019 Jun; 24(5):623-629. PubMed ID: 30457414
[TBL] [Abstract][Full Text] [Related]
19. Glycyrrhetinic Acid-Mediated Polymeric Drug Delivery Targeting the Acidic Microenvironment of Hepatocellular Carcinoma.
Zhang J; Zhang M; Ji J; Fang X; Pan X; Wang Y; Wu C; Chen M
Pharm Res; 2015 Oct; 32(10):3376-90. PubMed ID: 26148773
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory effect of norcantharidin on the growth of human gallbladder carcinoma GBC-SD cells in vitro.
Fan YZ; Fu JY; Zhao ZM; Chen CQ
Hepatobiliary Pancreat Dis Int; 2007 Feb; 6(1):72-80. PubMed ID: 17287171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
